SIGFOX
28.2.2020 12:18:09 CET | Business Wire | Press release
An Post, the leading mails, parcels and ecommerce logistics company in Ireland, has contracted VT-IoT, the operator of Ireland’s Sigfox 0G network to revolutionise their supply chain with IoT tracking devices as part of their innovative and fast-moving digital transformation strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200228005183/en/
As masters of delivery, An Post Mails & Parcels is rapidly changing from the old world of traditional letters to the new world of ecommerce parcel logistics and B2B services for Irish and international businesses. An Post runs Ireland’s largest fleet, including the country’s largest fleet of electric vehicles. It recently opened its new fully automated Dublin Parcel Hub and its operational infrastructure includes a large volume of returnable transport units such as roll cages and containers.
To provide an efficient and cost-effective service, An Post require a systematically integrated operational process. The roll cages and containers in which parcels are transported must be available every day in the required quantities in the Company’s mails hubs across the country.
With the advance of revolutionary Internet of Things (IoT) technology, VT and Sigfox are providing An Post with the solution they need to optimise their supply chain. Smart tracking devices empower An Post to monitor the location of their assets nationwide, even outside their own supply chain. Using Sigfox, the world’s leading IoT service provider and first global 0G network operator, has eliminated the barriers associated with traditional tracking technologies: price, battery life and coverage, by providing low cost, low power connectivity over a single global network today available in more than 70 countries.
“VT’s state-of-the-art solution has resulted in significantly increased transparency in our postal distribution network, ensuring world class quality of service for our customers and lower operational costs through improved containerisation efficiency”, explains Mark Devine, National Engineering Maintenance & Performance Manager, An Post .
“Our collaboration with An Post is an exciting step forward into the future of industrial IoT and a key milestone toward connecting billions of IoT devices globally on the Sigfox 0G network. We are confident our solutions have the power to truly revolutionise the way logistics and supply chain companies do business, resulting in significantly reduced costs and increased efficiencies .” Mark Bannon, CEO, VT.
““We are delighted to support An Post in this new era of industry 4.0, where we are making the once untraceable now entirely visible to organisations. We continue to deliver benefits to Postal organisations, like An Post in Ireland, DHL in Germany and Posti in Finland. This is a key vertical for Sigfox, where we strive to deliver value and thought leadership in Global Supply Chain & Logistics." Glen Robinson, SVP Global Sales & Marketing, Sigfox.
About An Post
An Post provides world-class mails, e-commerce parcels, financial and communications services to national and international business. It delivers two million items of mail to 2.2 million address points nationwide every working day, as well as evening and weekend parcels deliveries.
About VT
VT is a 0G IoT network operator and a pioneer of IoT solutions within the Supply Chain and Aerospace markets. Our purpose is to empower our enterprise users to transform their business models and operations through our leading-edge device to cloud 0G solutions. Our nationwide Sigfox IoT telecoms network currently delivers over 95% geographical coverage to Ireland – we are passionate about enabling every person, home and business to benefit from 0G IoT.
About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox’s unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.
Today, the network is available in 70 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005183/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
